Hua Bai

2.5k total citations · 2 hit papers
43 papers, 1.3k citations indexed

About

Hua Bai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Hua Bai has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Hua Bai's work include Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Research Studies (9 papers). Hua Bai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Research Studies (9 papers). Hua Bai collaborates with scholars based in China, United States and Sweden. Hua Bai's co-authors include Jie Wang, Zhijie Wang, Jianchun Duan, Kailun Fei, Xin Wang, Jianchun Duan, Jiachen Xu, Zhuoran Yao, Rui Wan and Yanhua Tian and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hua Bai

42 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

2019 249 citations Jianchun Duan, Hua Bai et al. profile →
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis

2021 160 citations Zhuoran Yao, Hua Bai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hua Bai China	17	858	422	263	200	172	43	1.3k
David J. Byrne Australia	20	627 0.7×	295 0.7×	233 0.9×	333 1.7×	342 2.0×	51	1.2k
Jason R. Brown United States	12	1.2k 1.4×	358 0.8×	562 2.1×	192 1.0×	253 1.5×	54	1.5k
Stefania Scarpino Italy	20	355 0.4×	277 0.7×	181 0.7×	373 1.9×	205 1.2×	50	1.4k
Runbo Zhong China	18	715 0.8×	440 1.0×	248 0.9×	275 1.4×	171 1.0×	89	1.1k
Seigo Minami Japan	19	584 0.7×	465 1.1×	109 0.4×	304 1.5×	98 0.6×	82	1.2k
Kazuhito Funai Japan	22	528 0.6×	673 1.6×	146 0.6×	515 2.6×	251 1.5×	127	1.4k
Joohee Sul United States	17	491 0.6×	565 1.3×	138 0.5×	365 1.8×	328 1.9×	26	1.7k
Ahmed Younes United States	22	589 0.7×	310 0.7×	427 1.6×	301 1.5×	150 0.9×	60	1.2k
Jennifer Landsberg Germany	23	676 0.8×	264 0.6×	454 1.7×	595 3.0×	231 1.3×	58	1.4k
Noriyuki Okonogi Japan	19	440 0.5×	403 1.0×	221 0.8×	149 0.7×	100 0.6×	88	1.1k

Countries citing papers authored by Hua Bai

Since Specialization

Citations

This map shows the geographic impact of Hua Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Bai more than expected).

Fields of papers citing papers by Hua Bai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Bai. The network helps show where Hua Bai may publish in the future.

Co-authorship network of co-authors of Hua Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Bai. A scholar is included among the top collaborators of Hua Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Bai. Hua Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ren, Xinyu, Zhou Yu, Shasha Jia, et al.. (2025). OsOFP9 regulates diverse key traits of rice by integrating multiple plant hormones. The Plant Journal. 121(5). e70044–e70044. 3 indexed citations

Guo, Yufeng, Yang Wang, Jianchun Duan, et al.. (2024). Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy. Heliyon. 10(16). e35940–e35940.

Han, Jiefei, Alexandre Reuben, Jianjun Zhang, et al.. (2024). Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature Communications. 15(1). 1199–1199. 7 indexed citations

Zeng, Hongmei, et al.. (2024). Correlation between abnormal cellular immune and changes of magnetic resonance spectroscopy in patients with Alzheimer’s disease. Neurochemistry International. 176. 105737–105737. 1 indexed citations

Bai, Hua, et al.. (2024). Correlative factors of poor prognosis and abnormal cellular immune function in patients with Alzheimer’s disease. World Journal of Clinical Cases. 12(6). 1063–1075. 1 indexed citations

Bai, Hua, et al.. (2023). Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. Frontiers in Oncology. 12. 1099304–1099304. 10 indexed citations

Bai, Hua, et al.. (2023). Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC. International Journal of Molecular Sciences. 24(19). 14521–14521. 7 indexed citations

Wang, Lu, et al.. (2023). Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer. Frontiers in Immunology. 14. 1265865–1265865. 12 indexed citations

Wang, Chao, Kailun Fei, Lihui Liu, et al.. (2023). Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment. Thoracic Cancer. 14(19). 1843–1856. 9 indexed citations

10.

Han, Lingli, et al.. (2022). The Prevalence of Fear of Childbirth and Its Association With Intolerance of Uncertainty and Coping Styles Among Pregnant Chinese Women During the COVID-19 Pandemic. Frontiers in Psychiatry. 13. 935760–935760. 22 indexed citations

11.

Zhao, Jie, Hua Bai, Jianchun Duan, et al.. (2021). Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. SHILAP Revista de lepidopterología. 2(1). 41–49. 3 indexed citations

12.

Liu, Lihui, Hua Bai, Chao Wang, et al.. (2021). Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology. 16(7). 1099–1117. 92 indexed citations

13.

Sun, Yiting, Jianchun Duan, Wenfeng Fang, et al.. (2021). Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Medicine. 19(1). 239–239. 19 indexed citations

14.

Zhang, Fan, Hua Bai, Ranran Gao, et al.. (2020). Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunology Immunotherapy. 69(12). 2599–2611. 27 indexed citations

15.

Duan, Jianchun, Zhijie Wang, Lin Lin, et al.. (2020). <p>The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study</p>. Cancer Management and Research. Volume 12. 11351–11358. 3 indexed citations

16.

Tian, Yanhua, Jiachen Xu, Qian Chu, et al.. (2020). A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine. 18(1). 232–232. 22 indexed citations

17.

Han, Jiefei, Jianchun Duan, Hua Bai, et al.. (2019). TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(1). 146–154. 177 indexed citations

18.

Yu, Jiangyong, Shuhang Wang, Wei Zhao, et al.. (2018). Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. Clinical Cancer Research. 24(9). 2148–2158. 47 indexed citations

19.

Wang, Liqiang, Hua Bai, & Yifei Huang. (2015). [Analysis of clinic results and complication associated with Boston I keratoprosthesis].. PubMed. 51(9). 673–6. 1 indexed citations

20.

Xu, Fei, Jingxun Wu, Cong Xue, et al.. (2012). Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and Therapy. 5. 439–439. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact